VENUS REMEDIES LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 359.6 INR | +0.28% |
|
-5.90% | -11.50% |
| 13/06 | Venus Remedies Bags Tender from UNICEF for Antibiotic Ceftriaxone | MT |
| 30/05 | Venus Remedies Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 | CI |
| Sales 2022 | 5.99B 71.78M | Sales 2023 | 5.56B 66.61M | Capitalization | 2.16B 25.96M |
|---|---|---|---|---|---|
| Net income 2022 | 407M 4.88M | Net income 2023 | 266M 3.19M | EV / Sales 2022 | 0.6 x |
| Net cash position 2022 | 4.11M 49.24K | Net cash position 2023 | 291M 3.48M | EV / Sales 2023 | 0.34 x |
| P/E ratio 2022 |
8.71
x | P/E ratio 2023 |
8.15
x | Employees | 998 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 52.78% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.28% | ||
| 1 week | -5.90% | ||
| Current month | +0.28% | ||
| 1 month | +13.66% | ||
| 3 months | +6.27% | ||
| 6 months | -11.24% | ||
| Current year | -11.50% |
1 week
346.00
386.50
1 month
290.20395.00
Current year
281.10430.00
1 year
222.00430.00
3 years
145.80639.00
5 years
18.80639.00
10 years
18.80639.00
| Managers | Title | Age | Since |
|---|---|---|---|
Ashutosh Jain
CEO | Chief Executive Officer | 47 | 01/07/01 |
Pawan Chaudhary
CHM | Chairman | 60 | 15/89/15 |
Jitendra Singh
ADM | Chief Administrative Officer | - | 01/99/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gilbert Wenzel
BRD | Director/Board Member | 68 | - |
Peeyush Jain
BRD | Director/Board Member | 52 | - |
Ashutosh Jain
CEO | Chief Executive Officer | 47 | 01/07/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 01/24/01 | 359.6 | +0.28% | 46 381 |
| 28/24/28 | 358.6 | +2.62% | 66,405 |
| 27/24/27 | 349.4 | -4.67% | 95,295 |
| 26/24/26 | 366.5 | -1.94% | 55,639 |
| 25/24/25 | 373.8 | -2.19% | 39,088 |
Delayed Quote NSE India S.E., July 01, 2024 at 03:51 pm IST
More quotes
Venus Remedies Ltd is a research-based pharmaceutical company. The Company is a global injectable manufacturer, possessing a wide product basket catering to therapeutic segments of anti-infective specially in antimicrobial resistance (AMR), oncology, skin and wound care and pain management. The Company operates in the Pharmaceutical Formulation segment. It manufactures products catering to the critical care and super specialty segments. The Company's product portfolio includes formulations such as injectables, tablets, and topical preparations. The Company offers solutions in the domains of antimicrobial resistance (AMR), oncology, skin & wound care, neurology, anticoagulants, pain management, herbal portfolio and disinfectants. Its focus therapy areas include medicine, surgery, neuro and orthopedics. The Companyâs brands include Potentox, Vancoplus Combi, Tobracef, Supime, Zydotum, Neurotol, Trois, Septiloc, Mucomelt, Ventaful and Nervolize. It has three manufacturing facilities.
Sector
Pharmaceuticals
Calendar
13/08/2024
- Q1 2025 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +55.32% | 815B | |
| +43.22% | 641B | |
| -6.75% | 352B | |
| +13.56% | 314B | |
| +10.68% | 303B | |
| +16.19% | 242B | |
| +2.21% | 224B | |
| +13.35% | 218B | |
| +8.48% | 168B |
- Stock Market
- Equities
- VENUSREM Stock
- VENUSREM Stock
